Target intelligence / Profile preview

D-alanyl-D-alanine terminus of Lipid II

Molecular classification
Other (structural motif of peptidoglycan/Lipid II), Antibiotic target (vancomycin binding site)
01

Overview

The D-alanyl-D-alanine terminus refers to the C-terminal dipeptide of the pentapeptide stem on the peptidoglycan precursor Lipid II[1][8]. Lipid II is a crucial molecule in bacterial cell wall synthesis, serving as the primary building block for peptidoglycan polymerization and cross-linking[5][6]. The D-Ala-D-Ala motif is highly solvent-accessible and flexible, functioning as the recognition site for bacterial transpeptidase enzymes and as the primary binding site for many antibiotics, notably vancomycin and related glycopeptides[1][2]. Disruption of this motif by drugs effectively halts cell wall assembly, thereby inhibiting bacterial growth and survival[2][8]. Bacterial resistance mechanisms (e.g., D-Ala-D-Lac replacement) exploit this site to evade antibiotic binding[2][8]. This motif does not represent a conventional receptor, enzyme, or transporter, but is nonetheless a validated and essential therapeutic target within bacterial physiology.

Other names
D-Ala-D-Ala terminusD-alanyl-D-alanine moietypeptidoglycan C-terminal dipeptide
02

Mechanism of action

Drug binding to D-Ala-D-Ala motif inhibits transpeptidase-mediated crosslinking of peptidoglycan, blocking cell wall synthesis and causing bacteriolysis

03

Biological functions

Peptidoglycan biosynthesisStructural integrity of bacterial cell wallInteraction site for cell wall transpeptidases and antibiotics
04

Disease associations

Infection (central to bacterial growth and survival)
05

Safety considerations

Bacterial resistance due to structural modifications (such as replacement of D-Ala-D-Lac in vancomycin-resistant strains)Potential for off-target toxicity from some antibiotics in clinical use
06

Interacting drugs

Vancomycin

5 more in the full profile.

Beyond the preview

Go deeper on D-alanyl-D-alanine terminus of Lipid II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-alanyl-D-alanine terminus of Lipid II.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call